SEC Form 4 · accession 0001144204-16-116711
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Daniel Gedeon Teper
Officer — CEO · Director · 10% Owner
Period of report
Aug 4, 2016
Accepted (ET)
Aug 4, 2016 · 9:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 4, 2016 | P | 937,500 | $0.38 | A | 5,748,405 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2 | $0.38 | Jun 24, 2016 | A | 300,000 | A | — | Jun 24, 2026 | Common Stock | 300,000 | 1,546,751 | D |
Explanation of responses
- F1Shares issued upon repayment of a $356,250 promissory note at the conversion price of $0.38 per share.
- F2The stock options shall vest immediately on the date of grant.